Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Initial experimentations already showed promising results. The team will now embark on a three-year-long study of this device on people suffering from chronic insomnia to test the efficiency of the ...
The Princeton Psychotherapy Center, a leading provider of mental health care, is now offering specialized therapy options to help individuals struggling with social anxiety and insomnia. The center ...